As of Aug. 27, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.

Here’s the latest list of major overbought players in this sector.

Veeva Systems Inc (NYSE:VEEV)

  • On Aug. 26, Veeva Systems reported better-than-expected second-quarter financial results and raised its FY27 guidance above estimates. “AI is opening up the next big chapter for Veeva and life sciences,” said CEO Peter Gassner. “Vault CRM had its best quarter ever and Veeva Falcon accelerated rapidly. By bringing together deep industry applications, agents, data, and consulting, we are helping the industry drive new efficiencies from clinical to commercial and deliver better outcomes for patients.” The company’s stock gained around 38% over the past month and has a 52-week high of $310.50.
  • RSI Value: 74.7                                
  • VEEV Price Action: Shares of Veeva fell 0.8% to close at $244.91 on Wednesday.
  • Edge Stock Ratings: 85.20 Momentum score with Value at 34.93.

Revolution Medicines Inc (NASDAQ:RVMD)

  • On Aug. 26, the U.S. Food and Drug Administration (FDA) on Wednesday approved Revolution Medicines’ Rasonque (daraxonrasib) for metastatic pancreatic adenocarcinoma (PDAC). “The FDA approval of RASONQUE is a monumental step forward for patients with pancreatic cancer and for the oncology field,” said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. The company’s stock gained around 15% over the past month and has a 52-week high of $220.30.
  • RSI Value: 71.9
  • RVMD Price Action: Shares of Revolution Medicines gained 1.9% to close at $215.44 on Wednesday.

Pulse Biosciences Inc (NASDAQ:PLSE)

  • On Aug. 17, Needham analyst Mike Matson initiated coverage on Pulse Biosciences with a Buy rating and announced a price target of $58. The company’s stock gained around 47% over the past month and has a 52-week high of $50.90.
  • RSI Value: 70.5
  • PLSE Price Action: Shares of Pulse Biosciences fell 1.8% to close at $48.10 on Wednesday.

Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare.

Photo via Shutterstock